UNSPSC 51203606: Tresperimus

This classification denotes an immunosuppressant with the molecular formula C17H37N7O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 286F595V8H, chemically known as carbamic acid, (4-((3-aminopropyl)amino)butyl)-, 2-((6-((aminoiminomethyl)amino)hexyl)amino)-2-oxoethyl ester but more generally known as tresperimus, which bears US NIH Compound Identifier 3086680. European Medicines Agency schedules Tresperimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11241MIG.

UNSPSC 51203606 Tresperimus, a Commodity code, spans pharmaceutical products and medical supplies that state and local governments procure for public health, emergency response, and employee benefit programs — including naloxone and drug deactivation systems, medical and first aid supplies for fire rescue operations, generic pharmaceuticals distributed through state health agencies, and direct-to-manufacturer prescription fulfillment programs. The work solicited ranges from high-volume consumable purchases (respiratory equipment, cardiac electrodes, bandaging materials, oxygen delivery systems) to strategic pharmacy benefit initiatives that bypass traditional pharmaceutical benefit managers and wholesalers. Issuing bodies include county health departments (Seminole County, Florida), municipal fire and rescue services (City of Tampa), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across participating jurisdictions).

Recent activity concentrates in Florida, Texas, and Minnesota. Representative current opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually, due July 26, 2023 (posted June 30, 2026); the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, due March 13, 2026, with an estimated contract value of $700,000 and a Small Local Business Enterprise set-aside with a 5% bid discount; Minnesota's MMCAP RFP for generic multi-source pharmaceuticals and OTC products serving state and local facilities across multiple states, proposals due March 26, 2026; and the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs, due April 3, 2026, designed to gather vendor capability information before issuing a formal RFP. The Tampa and MMCAP solicitations show active procurement momentum, while the Texas RFI signals emerging state interest in alternative pharmacy supply models.